Skip to content
HowShorted

Puma Biotechnology Inc short interest in 2022

In 2022, Puma Biotechnology Inc's disclosed short interest ran from 6.27% of shares outstanding on 14 Jan 2022 to 1.93% on 30 Dec 2022, a change of -4.34 percentage points. The year's high was 7.75% on 31 May 2022 and its low 1.93% on 30 Dec 2022, averaging 5.08% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.22 days on 14 Oct 2022. Full history: Puma Biotechnology Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Puma Biotechnology Inc in 2022

2022 in figures

Start of year
6.27% (14 Jan 2022)
End of year
1.93% (30 Dec 2022)
Change
-4.34 pp
High
7.75% (31 May 2022)
Low
1.93% (30 Dec 2022)
Average
5.08%
Highest days to cover
14.22 (14 Oct 2022)
SEC filings marked
8

Every report in 2022

Puma Biotechnology Inc short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.27%2.95
31 Jan 20226.01%3.57
15 Feb 20225.63%6.79
28 Feb 20225.73%8.16
15 Mar 20226.95%4.5010-K filed, results (8-K)
31 Mar 20227.67%6.17
14 Apr 20227.56%8.48
29 Apr 20227.07%10.46
13 May 20227.40%6.4510-Q filed, results (8-K)
31 May 20227.75%10.35
15 Jun 20227.68%6.73
30 Jun 20224.46%2.37
15 Jul 20224.13%6.02
29 Jul 20223.98%10.03
15 Aug 20224.02%5.5610-Q filed, results (8-K)
31 Aug 20223.97%10.19
15 Sep 20223.88%8.45
30 Sep 20223.50%10.02
14 Oct 20223.35%14.22
31 Oct 20223.34%13.47
15 Nov 20223.28%4.3410-Q filed, results (8-K)
30 Nov 20223.30%2.80
15 Dec 20223.12%2.91
30 Dec 20221.93%2.03

See also: Puma Biotechnology Inc's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.